drugset / Trial / NCT07229313
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Timeline
- Start
- 2025-11-13
- Primary completion
- 2028-03-31
- Completion
- 2030-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KIVU-107 | Other / unclassified | — | Intravenous |
Indications
No indication recorded.